pemetrexed+cisplatin

Phase 3Small molecule

pemetrexed+cisplatin is one of 89 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerRecruiting

Soft Tissue SarcomaRecruiting

Non-Small Cell Lung CancerPhase 3

Recruiting

Soft Tissue SarcomaPhase 2

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Nano-Crystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

1 2

Anktiva

SSWOG Cancer Research Network

Phase 3

1 3

Carboplatin/paclitaxel

AstraZeneca

Phase 3

3 4

pemetrexed+cisplatin

AstraZeneca

Phase 3

4 5

Remeron

OOrganon and Co

Preclinical

1 6

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 8

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 9

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—10

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Non-Small Cell Lung Cancer (NSCLC)

NCT03775486

Q3 2027

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT04035486

Q4 2027

Phase 2Recruiting

Soft Tissue Sarcoma

NCT04605770

Q2 2030

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT05061550

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer4 trials

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Completed· Pfizer logo

Pfizer·Phase 3·NCT01639001·207 enrolled

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

Completed·—·Phase 2·NCT01204307·101 enrolled

A Phase III, Open-label, Randomized Study of Osimertinib With or Without Platinum Plus Pemetrexed Chemo, as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2).

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04035486·587 enrolled

Show 1 more trial

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT05061550·630 enrolled

Cisplatin1 trial

Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC

Unknown status·GGuangzhou Medical University·Phase 2·NCT03374280·178 enrolled

Soft Tissue Sarcoma1 trial

Pemetrexed, Cisplatin With Soft Tissue Sarcoma

Recruiting·YYonsei University·Phase 2·NCT04605770·164 enrolled

Non-squamous NSCLC1 trial

Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC

Terminated·SSpanish Lung Cancer Group·Phase 2·NCT01088906·57 enrolled

Malignant Pleural Mesothelioma1 trial

Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma

Withdrawn·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02639767

2 more indications

Chemotherapy1 trial

Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT02436733·64 enrolled

Non-small Cell Lung Cancer (NSCLC)1 trial

A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab Plus Olaparib Combination Therapy Compared With Durvalumab Monotherapy as Maintenance Therapy in Patients Whose Disease Has Not Progressed Following Standard of Care Platinum-Based Chemotherapy With Durvalumab in First Line Stage IV Non Small Cell Lung Cancer (ORION)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT03775486·401 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for pemetrexed+cisplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pemetrexed+cisplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pemetrexed+cisplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

pemetrexed+cisplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2027

Q4 2027

Q2 2030

Trials by Indication[1]

Non-Small Cell Lung Cancer4 trials

Cisplatin1 trial

Soft Tissue Sarcoma1 trial

Non-squamous NSCLC1 trial

Malignant Pleural Mesothelioma1 trial

Chemotherapy1 trial

Non-small Cell Lung Cancer (NSCLC)1 trial

References

Drug Info

Quick Facts

Related News